The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.
 
Marc Peeters
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Speakers' Bureau - Amgen
Research Funding - Amgen (Inst); Amgen (Inst)
Travel, Accommodations, Expenses - Amgen; Amgen
 
Tae Won Kim
Honoraria - Amgen; Lilly
Research Funding - Bayer (Inst); Merck Serono (Inst); Roche (Inst)
 
Jin Li
Research Funding - Merck (Inst); Roche (Inst)
 
Stefano Cascinu
Consulting or Advisory Role - Amgen; Bayer; Lilly
 
Paul Ruff
Honoraria - Amgen; Pfizer; Sanofi
Research Funding - Amgen (Inst); Merck (Inst); Novartis (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Novartis; Pfizer; Roche
 
Attili Venkatasatya Suresh
No Relationships to Disclose
 
Anne Thomas
Consulting or Advisory Role - Lilly; Roche
 
Sergei Tjulandin
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Sanofi
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Boehringer Ingelheim; Merck Serono
 
Xuesong Guan
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Tien Hoang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Other Relationship - Amgen
 
Yong Jiang Hei
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Timothy Jay Price
Consulting or Advisory Role - Amgen; Merck